

# Loreto Carmona

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4502831/loreto-carmona-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

277 papers	23,895 citations	58 h-index	152 g-index
327 ext. papers	28,420 ext. citations	3.2 avg, IF	6.24 L-index

#	Paper	IF	Citations
277	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2197-223	4.0	5768
276	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , <b>2012</b> , 380, 2163-96	4.0	4971
275	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 2122-7		707
274	The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1316-22	2.4	613
273	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 859-866	2.4	575
272	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1766-72		501
271	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , <b>2010</b> , 36, 1185-206	13.6	360
270	The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 1040-5	2.4	350
269	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 68, 1006-16	2.4	320
268	Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 375-81	2.4	316
267	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 756-61		313
266	Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 116-24		298
265	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1269-74	2.4	245
264	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 644-51	2.4	241
263	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 930-942	2.4	210
262	Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2248-56		208
261	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R29	5.7	200

260	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 328-35	2.4	182
259	Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 935-42	2.4	180
258	The prevalence of rheumatoid arthritis in the general population of Spain. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 88-95		163
257	Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 897-900	2.4	157
256	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 880-5	2.4	154
255	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1680-5	2.4	145
254	Rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2010</b> , 24, 733-45	5.3	145
253	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 8-13	2.4	143
252	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 16-24	2.4	142
251	A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. <i>Seminars in Arthritis and Rheumatism</i> , <b>2010</b> , 40, 2-14.e1	5.3	136
250	Increased risk of tuberculosis in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1436-9	4.1	136
249	Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONER) extended report. <i>Rheumatology</i> , <b>2007</b> , 46, 1309-15	3.9	134
248	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 851-858	2.4	133
247	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R72	5.7	129
246	Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 49, 64-70		128
245	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e250-e253	14.2	125
244	Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 177-82	2.4	121
243	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 965-73	2.4	121

242	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1974-1979	2.4	112
241	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. <i>Rheumatology</i> , <b>2014</b> , 53, 1872-85	3.9	101
240	EULAR/PreS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 639-646	2.4	99
239	Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2009</b> , 38, 312-9	5.3	97
238	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1544-1549	2.4	96
237	Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 117-27	9.5	95
236	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey. <i>RMD Open</i> , <b>2016</b> , 2, e000166	5.9	94
235	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1067-1077	9.5	91
234	Economic burden of knee and hip osteoarthritis in Spain. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 158-65		89
233	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1958-67	2.4	85
232	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1751-5	2.4	84
231	Survival, mortality and causes of death in inflammatory myopathies. <i>Autoimmunity</i> , <b>2006</b> , 39, 205-15	3	79
230	Cancer in patients with rheumatic diseases exposed to TNF antagonists. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 71-80	5.3	76
229	The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. <i>Rheumatology</i> , <b>2008</b> , 47, 1088-92	3.9	76
228	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1596-602	2.4	71
227	Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 40-6	4.1	71
226	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 902-5	2.4	69
225	Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 37, 388-97	5.3	67

224	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1870-1882	2.4	67
223	Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 40, 314-23	5.3	61
222	Reduction of bone mass in women after bone marrow transplantation. <i>Calcified Tissue International</i> , <b>1997</b> , 60, 343-7	3.9	59
221	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 9-17	5.3	58
220	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 382-5	2.4	58
219	Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. <i>Medicina Clínica</i> , <b>2011</b> , 137, 533-40	1	56
218	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 383-8	13.6	55
217	Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. <i>Seminars in Arthritis and Rheumatism</i> , <b>2010</b> , 39, 285-93	5.3	51
216	A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 4002-6		49
215	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1137-1146	2.4	49
214	Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. <i>Rheumatology</i> , <b>2008</b> , 47, 464-6	3.9	48
213	Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 42, 89-103	5.3	46
212	Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 893-7	4.1	46
211	Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Mulhearn. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	46
210	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 476-479	2.4	45
209	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 871-82	2.4	45
208	Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology International</i> , <b>2014</b> , 34, 953-61	3.6	44
207	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis: A Cross Sectional and Case Control Analysis Within the SUN Cohort. <i>Medicine (United States)</i> , <b>2015</b> , 94, e0924	1.8	43

206	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica</i> , <b>2012</b> , 8, 334-41	0.9	42
205	Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>RMD Open</i> , <b>2018</b> , 4, e000734	5.9	40
204	Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. <i>Rheumatology International</i> , <b>2015</b> , 35, 445-58	3.6	39
203	Systematic review and critical appraisal of transitional care programmes in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 372-379	5.3	38
202	Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 2024-31	4.7	38
201	Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 40, 330-7	5.3	38
200	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 15-24	2.4	38
199	Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 55, 751-6		37
198	Predictors of rate of return to work after surgery for carpal tunnel syndrome. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 11, 298-305		37
197	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , <b>2019</b> , 5, e001014	5.9	37
196	Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1350-5	2.4	36
195	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. <i>Rheumatology</i> , <b>2011</b> , 50, 1999-2004	3.9	36
194	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1145-9	2.4	35
193	Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 44-52	5.3	35
192	Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. <i>Cochrane Database of Systematic Reviews</i> , <b>2005</b> , CD002229		35
191	Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 524-33	5.3	34
190	Limited value of ultrasound assessment in patients with poor outcome after carpal tunnel release surgery. <i>Scandinavian Journal of Rheumatology</i> , <b>2010</b> , 39, 409-12	1.9	34
189	Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. <i>Lupus</i> , <b>2015</b> , 24, 1135-42	2.6	33



188	A health system program to reduce work disability related to musculoskeletal disorders. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 404-14	8	33
187	The epidemiology of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2019</b> , 33, 101477	5.3	33
186	A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 827-30	2.4	32
185	Prevalence of Paget's disease of bone in Spain. <i>Bone</i> , <b>2008</b> , 43, 1006-9	4.7	32
184	Denosumab for the treatment of osteoporosis: a systematic literature review. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 42-52	0.9	30
183	An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. <i>Journal of Clinical Rheumatology</i> , <b>2011</b> , 17, 349-55	1.1	30
182	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , <b>2011</b> , 50, 85-92	3.9	29
181	Transitional care for rheumatic conditions in Europe: current clinical practice and available resources. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 49	3.5	28
180	Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 697-704	4.1	28
179	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 963-9	2.4	27
178	Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. <i>Reumatología Clínica</i> , <b>2014</b> , 10, 89-93	0.9	27
177	Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, R138	5.7	27
176	Prognostic factors in short-term disability due to musculoskeletal disorders. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 489-96		26
175	Observed and expected frequency of comorbid chronic diseases in rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 418-21	2.4	26
174	Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 159-65	4.1	26
173	Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 559-69	2.2	26
172	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1263-1268	2.4	25
171	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. <i>Rheumatology</i> , <b>2014</b> , 53, 353-60	3.9	25

170	Musculoskeletal work disability for clinicians: time course and effectiveness of a specialized intervention program by diagnosis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 335-42		25
169	The EULAR Outcome Measures Library: an evolutionary database of validated patient-reported instruments. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 475-6	2.4	24
168	Efficacy and safety of home-based exercises versus individualized supervised outpatient physical therapy programs after total knee arthroplasty: a systematic review and meta-analysis. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , <b>2017</b> , 25, 3340-3353	5.5	24
167	Failure to reach uric acid target of . <i>RMD Open</i> , <b>2019</b> , 5, e001015	5.9	24
166	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , <b>2015</b> , 34, 1961-7	3.9	23
165	Weather conditions may worsen symptoms in rheumatoid arthritis patients: the possible effect of temperature. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 226-8	0.9	23
164	2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1278-1285	2.4	23
163	Patterns and Consequences of Multimorbidity in the General Population: There is No Chronic Disease Management Without Rheumatic Disease Management. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 12-20	4.7	22
162	Is spinal mobility in patients with spondylitis determined by age, structural damage, and inflammation?. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 74-9	4.7	22
161	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. <i>Rheumatology International</i> , <b>2017</b> , 37, 1239-1248	3.6	21
160	Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?. <i>Reumatología Clínica</i> , <b>2016</b> , 12, 307-312	0.9	21
159	Management of the Psychological Impact of Inflammatory Bowel Disease: Perspective of Doctors and Patients-The ENMENTE Project. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1492-1498	4.5	21
158	Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. <i>Patient Preference and Adherence</i> , <b>2017</b> , 11, 1243-1252	2.4	21
157	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	21
156	Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 423-430	2.2	20
155	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 126-132	2.4	19
154	Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. <i>Rheumatology International</i> , <b>2015</b> , 35, 1127-37	3.6	19
153	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , <b>2015</b> , 54, 1074-1079	3.9	19



152	Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. <i>Rheumatology International</i> , <b>2017</b> , 37, 1195-1202	3.6	18
151	The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. <i>Journal of rheumatology Supplement, The</i> , <b>2014</b> , 92, 15-25		18
150	Different clinical expression of patients with ankylosing spondylitis according to gender in relation to time since onset of disease. Data from REGISPONSER. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 221-5	0.9	18
149	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 41-50	2.9	18
148	Prognostic factors for long-term work disability due to musculoskeletal disorders. <i>Rheumatology International</i> , <b>2012</b> , 32, 3831-9	3.6	18
147	Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 150-155	4.7	17
146	Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset. <i>Rheumatology International</i> , <b>2015</b> , 35, 1615-24	3.6	17
145	The burden of disease in Spain: results from the global burden of disease study 2010. <i>BMC Medicine</i> , <b>2014</b> , 12, 236	11.4	17
144	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , <b>2014</b> , 34, 1059-63	3.6	17
143	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2129639	10.4	17
142	Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1850-5	4.1	16
141	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , <b>2017</b> , 37, 1227-1236	3.6	15
140	Abatacept use in rheumatoid arthritis: evidence review and recommendations. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 5-17	0.9	15
139	Interleukin-1 inhibitors for acute gout. <i>The Cochrane Library</i> , <b>2014</b> , CD009993	5.2	15
138	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). <i>RMD Open</i> , <b>2021</b> , 7,	5.9	15
137	Weather conditions and their effect on seasonality of incident osteoporotic hip fracture. <i>Archives of Osteoporosis</i> , <b>2018</b> , 13, 28	2.9	14
136	Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). <i>Rheumatology International</i> , <b>2014</b> , 34, 401-6	3.6	14
135	Management of rheumatoid arthritis in Spain (emAR II). Clinical characteristics of the patients. <i>Reumatología Clínica</i> , <b>2012</b> , 8, 236-42	0.9	14

- 134 Trends in osteoporotic hip fracture epidemiology over a 17-year period in a Spanish population: Alcorc 1999-2015. *Archives of Osteoporosis*, **2017**, 12, 84 2.9 13
- 133 Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. *Rheumatology International*, **2018**, 38, 975-983 3.6 13
- 132 Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. *Journal of rheumatology Supplement, The*, **2014**, 92, 3-8 13
- 131 Effectiveness of a clinical practice intervention in early rheumatoid arthritis. *Arthritis Care and Research*, **2012**, 64, 321-30 4.7 13
- 130 Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutionary database model of validated patient-reported outcomes. *Seminars in Arthritis and Rheumatism*, **2017**, 46, 609-614 5.3 13
- 129 Variability in resource consumption in patients with spondyloarthritis in Spain. Preliminary descriptive data from the emAR II study. *Reumatología Clínica*, **2012**, 8, 114-9 0.9 13
- 128 Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. *Annals of the Rheumatic Diseases*, **2019**, 78, 1291-1294 3.4 12
- 127 SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. *Annals of the Rheumatic Diseases*, **2021**, 2.4 12
- 126 Dietary supplements for chronic gout. *The Cochrane Library*, **2014**, CD010156 5.2 11
- 125 Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. *Reumatología Clínica*, **2009**, 5, 252-8 0.9 11
- 124 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. *Annals of the Rheumatic Diseases*, **2020**, 2.4 11
- 123 Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. *Lancet Rheumatology, The*, **2021**, 3, e855-e864 14.2 11
- 122 Second Hip Fracture: Incidence, Trends, and Predictors. *Calcified Tissue International*, **2018**, 102, 619-626 3.9 11
- 121 Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. *Lancet Rheumatology, The*, **2021**, 3, e707-e714 14.2 11
- 120 Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. *Clinical and Experimental Rheumatology*, **2018**, 36, 382-388 2.2 11
- 119 Recommendations for the detection, study and referral of inflammatory low-back pain in primary care. *Reumatología Clínica*, **2015**, 11, 90-8 0.9 10
- 118 Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis. *Arthritis Care and Research*, **2013**, 65, 518-25 4.7 10
- 117 EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). *Annals of the Rheumatic Diseases*, **2021**, 80, 840-847 2.4 10

116	Barriers and Facilitators for the Practice of Physical Exercise in Patients With Spondyloarthritis: Qualitative Study of Focus Groups (EJES-3D). <i>Reumatología Clínica</i> , <b>2017</b> , 13, 91-96	0.9	9
115	Databases and registers: useful tools for research, no studies. <i>Rheumatology International</i> , <b>2014</b> , 34, 447-52	3.6	9
114	Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. <i>Reumatología Clínica</i> , <b>2014</b> , 10, 309-20	0.9	9
113	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161727	3.7	9
112	EULAR recommendations for intra-articular therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1299-1305	1.4	9
111	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1894-1898	4.1	8
110	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1545-8	2.4	8
109	Patient-physician collaboration in rheumatology: a necessity. <i>RMD Open</i> , <b>2017</b> , 3, e000499	5.9	8
108	Incidence of physical disability related to musculoskeletal disorders in the elderly: results from a primary care-based registry. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 89-93	4.7	8
107	Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 938-942	4.7	7
106	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	7
105	How good is to switch between biologics? A systematic review of the literature. <i>Acta Reumatológica Portuguesa</i> , <b>2007</b> , 32, 113-28	0.7	7
104	The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. <i>Adv Ther</i> (2017);34:91-108. doi:10.1007/s12325-016-0441-3. <i>Advances in Therapy</i> , <b>2017</b> , 34, 2173-2176	4.1	6
103	Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 350-355	5.3	6
102	Motivations and objections to implement a spondyloarthritis integrated care pathway. A qualitative study with primary care physicians. <i>Reumatología Clínica</i> , <b>2013</b> , 9, 85-9	0.9	6
101	Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. <i>Journal of rheumatology Supplement, The</i> , <b>2011</b> , 87, 54-8		6
100	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166691	3.7	6
99	Recommendations for the prescription of physical exercise for patients with spondyloarthritis. <i>Reumatología Clínica</i> , <b>2019</b> , 15, 77-83	0.9	6

98	Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. <i>Reumatología Clínica</i> , <b>2018</b> , 14, 346-359	0.9	5
97	The practical value of biologics registries in Africa and Middle East: challenges and opportunities. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 407-16	3.9	5
96	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>Reumatología Clínica (English Edition)</i> , <b>2013</b> , 9, 226-228	0.1	5
95	Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. <i>Rheumatology</i> , <b>2013</b> , 52, 331-6	3.9	5
94	Infections in patients with rheumatic diseases treated with TNF antagonists. <i>Current Pharmaceutical Biotechnology</i> , <b>2012</b> , 13, 1418-25	2.6	5
93	Prevalence of silent amyloidosis in RA and its clinical significance. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1013-4; author reply 1014	4.1	5
92	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1164-1167	4.1	4
91	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 870-876	5.3	4
90	High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1383-1388	4.1	4
89	Quality-of-care standards for early arthritis clinics. <i>Rheumatology International</i> , <b>2013</b> , 33, 2459-72	3.6	4
88	Despair on disparities. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1657-8	2.4	4
87	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 679009	4.9	4
86	Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	4
85	Is Obesity in Psoriatic Arthritis Associated With a Poorer Therapeutic Response and More Adverse Effects of Treatment With an Anchor Drug?. <i>Reumatología Clínica (English Edition)</i> , <b>2016</b> , 12, 307-312	0.1	4
84	Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. <i>Reumatología Clínica</i> , <b>2020</b> , 16, 116-119	0.9	4
83	The journey of the non-radiographic axial spondyloarthritis patient: the perspective of professionals and patients. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 591-600	3.9	4
82	Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV, Exacerbations, Oral Corticosteroids, Symptoms Score. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 2725-2731	5.4	4
81	Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. <i>Rheumatology International</i> , <b>2018</b> , 38, 2289-2296	3.6	4

80	The population impact of rheumatic and musculoskeletal diseases in relation to other non-communicable disorders: comparing two estimation approaches. <i>Rheumatology International</i> , <b>2018</b> , 38, 905-915	3.6	3
79	Reducing the need for central dual-energy X-ray absorptiometry in postmenopausal women: efficacy of a clinical algorithm including peripheral densitometry. <i>Calcified Tissue International</i> , <b>2013</b> , 93, 62-8	3.9	3
78	Denosumab for the treatment of osteoporosis: A systematic literature review. <i>Reumatología Clínica (English Edition)</i> , <b>2013</b> , 9, 42-52	0.1	3
77	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience. <i>Joint Bone Spine</i> , <b>2013</b> , 80, 438-40	2.9	3
76	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1423-1431	2.4	3
75	Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	3
74	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 990-1	4.1	3
73	Practical Aspects of Biological Thought Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis. <i>Reumatología Clínica</i> , <b>2020</b> , 16, 378-385	0.9	3
72	Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco by Kritz. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e87	2.4	3
71	Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 883-8	2.2	3
70	Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs. <i>Rheumatology International</i> , <b>2019</b> , 39, 1077-1082	3.6	2
69	The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. <i>PLoS ONE</i> , <b>2019</b> , 14, e0214717	3.7	2
68	Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial. <i>Physiotherapy</i> , <b>2020</b> , 108, 37-44	3	2
67	The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. <i>Rheumatology International</i> , <b>2018</b> , 38, 1735-1740	3.6	2
66	Treatment target and followup measures for patients with gout: a systematic literature review. <i>Journal of rheumatology Supplement, The</i> , <b>2014</b> , 92, 55-62		2
65	Practice guidelines for the use of subcutaneous abatacept. <i>Reumatología Clínica</i> , <b>2014</b> , 10, 218-26	0.9	2
64	A10.24 Switching Infliximab for New Alternatives: A Correspondence Analysis of Biologics, Reasons to Stop, and Time Periods. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A80.3-A81	2.4	2
63	Assessment of multiple organ systems in systemic lupus erythematosus: what will the new guidelines mean?. <i>International Journal of Clinical Rheumatology</i> , <b>2010</b> , 5, 291-297	1.5	2



62	More evidence on the dysautonomic nature of fibromyalgia: the association with short stature. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 1415-6		2
61	Ensuring the Consistency of Biosimilars. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 6733-6738	3.3	2
60	Patients' perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU-LIFE survey. <i>Musculoskeletal Care</i> , <b>2020</b> , 18, 568-574	1.6	2
59	Epidemiology and health-related services. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 104-9	5.3	2
58	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 649-657	4.7	2
57	Overview of changes in RMD epidemiology and outcome development in the last 10 years. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 169-173	5.3	2
56	Recommendaions for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. <i>Reumatología Clínica (English Edition)</i> , <b>2015</b> , 11, 90-98	0.1	1
55	An early intervention program for subacute physical disability related to musculoskeletal diseases in the elderly: a pilot study. <i>Rheumatology International</i> , <b>2015</b> , 35, 1183-91	3.6	1
54	Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. <i>Rheumatology International</i> , <b>2019</b> , 39, 2137-2145	3.6	1
53	Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF dans la polyarthrite rhumatoïde : expérience de trois centres. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2013</b> , 80, 527-528	0.1	1
52	Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations. <i>Reumatología Clínica (English Edition)</i> , <b>2013</b> , 9, 5-17	0.1	1
51	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatología Clínica (English Edition)</i> , <b>2011</b> , 7, 284-298	0.1	1
50	Biobadaser 2.0: analysis and trends in 2009. <i>Reumatología Clínica (English Edition)</i> , <b>2010</b> , 6, 240-243	0.1	1
49	Clinical composite measures of disease activity for diagnosis and followup of undifferentiated peripheral inflammatory arthritis: a systematic review. <i>Journal of rheumatology Supplement, The</i> , <b>2011</b> , 87, 48-53		1
48	Diagnostic and prognostic value of genetics in undifferentiated peripheral inflammatory arthritis: a systematic review. <i>Journal of rheumatology Supplement, The</i> , <b>2011</b> , 87, 38-44		1
47	Interleukin-1 inhibitors for acute gout <b>2012</b> ,		1
46	Intra-articular therapies: patient preferences and professional practices in European countries. <i>Rheumatology International</i> , <b>2021</b> , 42, 869	3.6	1
45	Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. <i>Immunotherapy</i> , <b>2021</b> , 13, 433-458	3.8	1



44	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1110-1115	2.4	1
43	Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 669688	4.9	1
42	Perceptions of Patients With Rheumatic Diseases Treated With Subcutaneous Biologicals on Their Level of Information: RHEU-LIFE Survey. <i>Reumatología Clínica (English Edition)</i> , <b>2019</b> , 15, 343-349	0.1	1
41	Severity indices in rheumatoid arthritis: A systematic review. <i>Reumatología Clínica</i> , <b>2019</b> , 15, 146-151	0.9	1
40	The EJS-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. <i>Rheumatology International</i> , <b>2018</b> , 38, 1277-1284	3.6	1
39	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1113-1116	5.3	1
38	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.. <i>RMD Open</i> , <b>2022</b> , 8,	5.9	1
37	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , <b>2019</b> , 15, 63-68	0.9	0
36	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. <i>Rheumatology International</i> , <b>2016</b> , 36, 1515-1523	3.6	0
35	PROMs for Fibromyalgia <b>2016</b> , 175-208		0
34	Clinical Composite Measures of Disease Activity and Damage Used to Evaluate Patients With Systemic Lupus Erythematosus: A Systematic Literature Review. <i>Reumatología Clínica (English Edition)</i> , <b>2014</b> , 10, 309-320	0.1	0
33	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica (English Edition)</i> , <b>2012</b> , 8, 334-341	0.1	0
32	Anti-TNF therapy and cancer. <i>Reumatología Clínica (English Edition)</i> , <b>2010</b> , 6, 102-105	0.1	0
31	Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy. <i>Reumatología Clínica (English Edition)</i> , <b>2008</b> , 4, 90-95	0.1	0
30	Severity Indices in Rheumatoid Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , <b>2019</b> , 15, 146-151	0.1	0
29	Perceptions of patients with rheumatic diseases treated with subcutaneous biologicals on their level of information: RHEU-LIFE Survey. <i>Reumatología Clínica</i> , <b>2019</b> , 15, 343-349	0.9	0
28	Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. <i>Reumatología Clínica (English Edition)</i> , <b>2018</b> , 14, 346-359	0.1	0
27	Effect of Weight Loss on Activity in Psoriatic Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , <b>2018</b> , 14, 207-210	0.1	0

26	Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit. <i>Reumatología Clínica (English Edition)</i> , <b>2019</b> , 15, 63-68	0.1
25	Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists. <i>Rheumatology International</i> , <b>2020</b> , 1	3.6
24	Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. <i>Reumatología Clínica (English Edition)</i> , <b>2020</b> , 16, 116-119	0.1
23	Practice Guidelines for the Use of Subcutaneous Abatacept. <i>Reumatología Clínica (English Edition)</i> , <b>2014</b> , 10, 218-226	0.1
22	Motivations and Objections to Implement a Spondyloarthritis Integrated Care Pathway. A Qualitative Study With Primary Care Physicians. <i>Reumatología Clínica (English Edition)</i> , <b>2013</b> , 9, 85-89	0.1
21	Facteur rhumatoïde et réponse aux anti-TNF dans la polyarthrite rhumatoïde: revue systématique et méta-analyse d'études observationnelles. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2014</b> , 81, 58-68	0.1
20	Variability in Resource Consumption in Patients With Spondyloarthritis in Spain. Preliminary Descriptive Data From the emAR II Study. <i>Reumatología Clínica (English Edition)</i> , <b>2012</b> , 8, 114-119	0.1
19	Management of Rheumatoid Arthritis in Spain (emAR II). Clinical Characteristics of the Patients. <i>Reumatología Clínica (English Edition)</i> , <b>2012</b> , 8, 236-242	0.1
18	Systematic review: Safety and efficacy of anti-TNF in elderly patients. <i>Reumatología Clínica (English Edition)</i> , <b>2011</b> , 7, 104-112	0.1
17	Characteristics of early arthritis units that may be associated with better referral efficiency: survey of SERAP units. <i>Reumatología Clínica (English Edition)</i> , <b>2011</b> , 7, 236-240	0.1
16	Characteristics of Paget's disease in Spain. Data from the National Paget's Register. <i>Reumatología Clínica (English Edition)</i> , <b>2009</b> , 5, 109-114	0.1
15	What are patients with early rheumatoid arthritis like in Spain? Description of the PROAR cohort. <i>Reumatología Clínica (English Edition)</i> , <b>2009</b> , 5, 115-120	0.1
14	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , <b>2021</b> , 11, CD010156	5.2
13	Predicting toxicity: biomarkers and the value of the patient's opinion. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 233-40	3.3
12	Practical aspects of biological treatment levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , <b>2020</b> , 16, 378-385	0.1
11	Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia. <i>Reumatología Clínica (English Edition)</i> , <b>2021</b> , 17, 150-154	0.1
10	Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , <b>2021</b> , 17, 101-108	1.6
9	Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab. <i>Reumatología Clínica (English Edition)</i> , <b>2022</b> , 18, 25-29	0.1

8	Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4
7	Centre-related variability in hospital admissions of patients with spondyloarthritis. <i>Rheumatology International</i> , <b>2016</b> , 36, 1301-8	3.6
6	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. <i>Reumatologia Clínica (English Edition)</i> , <b>2019</b> , 15, 77-83	0.1
5	Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4
4	Epidemiological Characteristics and Adverse Events of Patients with Psoriatic Arthritis Undergoing Treatment with Biological Therapies in Galicia. <i>Reumatologia Clínica</i> , <b>2021</b> , 17, 150-154	0.9
3	Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105172	2.9
2	Reducing bureaucracy in clinical trials, now is the time!. <i>RMD Open</i> , <b>2022</b> , 8,	5.9
1	Patient Perspectives on Long-Term Outcomes in Rheumatoid Arthritis. A Qualitative Study from the OMERACT Patient Outcomes in Longitudinal Studies Working Group.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 152028	5.3